Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$341 Mln
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
--
Debt to Equity
0
ROE
-16.43 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-4.15
CFO
$-328.01 Mln
EBITDA
$-347.07 Mln
Net Profit
$-350.39 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Inventiva Sa (IVA)
| 76.17 | 33.69 | 49.60 | 14.59 | -28.48 | -- | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Inventiva Sa (IVA)
| -52.32 | 1.26 | -67.35 | -5.79 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.65 | 200.22 | -- | 299.46 | |
| 7.10 | 178.41 | -- | -40.76 | |
| 1.77 | 182.31 | -- | -136.88 | |
| 0.62 | 20.76 | 5.15 | 33.7 |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. It develops Lanifibranor, for the... treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was incorporated in 2011 and is headquartered in Daix, France. Address: 50 rue de Dijon, Daix, France, 21121 Read more
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Dr. Pierre Broqua Ph.D.
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Dr. Pierre Broqua Ph.D.
Headquarters
Daix
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Inventiva Sa (IVA) stood at $ 68 Mln as on 30-Sep-24
The share price of Inventiva Sa (IVA) is $3.77 (NASDAQ) as of 24-Apr-2025 10:38 EDT. Inventiva Sa (IVA) has given a return of -28.48% in the last 3 years.
Inventiva Sa (IVA) has a market capitalisation of $ 341 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of Inventiva Sa (IVA) is 2.10 times as on 22-Apr-2025, a 9% discount to its peers’ median range of 2.30 times.
Since, TTM earnings of Inventiva Sa (IVA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Inventiva Sa (IVA) and enter the required number of quantities and click on buy to purchase the shares of Inventiva Sa (IVA).
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. It develops Lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was incorporated in 2011 and is headquartered in Daix, France. Address: 50 rue de Dijon, Daix, France, 21121
The CEO & director of Dr. Pierre Broqua Ph.D.. is Inventiva Sa (IVA), and CFO & Sr. VP is Dr. Pierre Broqua Ph.D..
There is no promoter pledging in Inventiva Sa (IVA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
18
|
|
|
16
|
|
|
2
|
| Inventiva Sa (IVA) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-518.59
|
|
Net Margin(%)
|
-540.52
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Inventiva Sa (IVA) was $0 Mln.
$-0.14
(
